What is the recommended dose for primaquine (Phosphogluconic acid dehydrogenase) prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Primaquine Prophylaxis Dosing

For terminal prophylaxis to prevent P. vivax and P. ovale relapses after exposure, the CDC recommends primaquine 15 mg base (26.3 mg salt) daily for 14 days. 1

Indication for Terminal Prophylaxis

  • Terminal prophylaxis is specifically indicated for persons with prolonged exposure in malaria-endemic areas, such as missionaries and Peace Corps volunteers, to eradicate dormant liver-stage parasites (hypnozoites) that cause relapses. 1

  • This regimen should be administered after leaving the endemic area to prevent relapse, not during active exposure. 1

Alternative Primary Prophylaxis Regimen

  • For primary prophylaxis (prevention during exposure rather than terminal prophylaxis), primaquine 30 mg base (0.5 mg/kg) daily has demonstrated 85-93% protective efficacy against both P. falciparum and P. vivax in clinical trials. 2

  • The major advantage of primaquine for primary prophylaxis is that it does not require pre-travel dosing and only needs to be continued for 3 days after leaving the malarious area, unlike other antimalarials. 2

  • This higher dose (30 mg base daily) was well-tolerated in 339 subjects taking it for 12-52 weeks, with only mild, transient methemoglobinemia (<13%, typically <6%). 2

Critical G6PD Deficiency Screening Requirement

  • Primaquine is absolutely contraindicated without G6PD testing for these prophylactic regimens, as the cumulative 14-day course poses significant hemolytic risk in G6PD-deficient individuals. 3, 4

  • The 14-day radical cure regimen (total dose 3.5-7 mg/kg) carries substantially higher hemolytic risk than single low-dose regimens, with nearly all reported primaquine-related deaths occurring after multiple dosing. 5

  • G6PD deficiency affects 3-30% of populations in malaria-endemic regions, making screening essential before prescribing prophylactic courses. 4

Important Caveats

  • The single low dose of 0.25 mg/kg used for P. falciparum gametocytocidal effect is NOT the same as prophylaxis dosing and carries minimal hemolytic risk even without G6PD testing. 6

  • Primaquine should be taken with food to minimize gastrointestinal side effects and optimize absorption. 2

  • For radical cure of active vivax malaria, primaquine should be given concurrently with chloroquine to first eliminate blood-stage parasites. 3

References

Guideline

Primaquine Prophylaxis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Primaquine for prevention of malaria in travelers.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003

Research

Primaquine: the risks and the benefits.

Malaria journal, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.